Intas becomes first Indian company to launch biosimilar in the EU

23 February 2015
biosimilars_samples_large

Indian biopharma company Intas has become the first Indian company to launch a biosimilar in highly regulated territories such as the European Union, the USA and Japan.

Its biosimilar, filgrastim, has been launched in Europe through Intas’ wholly-owned subsidiary Accord Healthcare, under the name Accofil.

Intas is also the only Indian company to have two of its products, filgrastim and peg-filgrastim, filed for registration in the USA, through its partner.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars